DMAC (DiaMedica Therapeutics) Institutional Ownership: 23.17% (As of Jul. 02, 2026)


DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $7.45
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics Institutional Ownership?

DiaMedica Therapeutics DMAC +5.53% 31 Institutional Ownership is 23.17% as of Jul. 02, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, DiaMedica Therapeutics's institutional ownership is 23.17%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, DiaMedica Therapeutics's Insider Ownership is 3.05%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, DiaMedica Therapeutics's Float Percentage Of Total Shares Outstanding is 67.10%.

DiaMedica Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Institutional Ownership Chart

DiaMedica Therapeutics Historical Data

The historical data trend for DiaMedica Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 9.39 9.32 8.37 8.99 8.65 8.67 8.79 8.49 8.52 8.95
DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 23.17% mean?
DiaMedica Therapeutics (DMAC) has a Institutional Ownership of 23.17% as of Jul. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Institutional Ownership too high?
DiaMedica Therapeutics' current Institutional Ownership is 23.17%. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Institutional Ownership compare to PRLD and RCKT?
DiaMedica Therapeutics' Institutional Ownership of 23.17% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Institutional Ownership is 23.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Institutional Ownership of 23.17%. The current Institutional Ownership is 23.17%. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Institutional Ownership is 23.17% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price